Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arvinas Inc (ARVN)

Arvinas Inc (ARVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 807,296
  • Shares Outstanding, K 64,224
  • Annual Sales, $ 263,400 K
  • Annual Income, $ -198,900 K
  • EBIT $ -102 M
  • EBITDA $ -113 M
  • 60-Month Beta 2.44
  • Price/Sales 3.16
  • Price/Cash Flow N/A
  • Price/Book 1.70

Options Overview Details

View History
  • Implied Volatility 66.30% (-15.13%)
  • Historical Volatility 82.45%
  • IV Percentile 20%
  • IV Rank 8.17%
  • IV High 218.75% on 02/10/25
  • IV Low 52.74% on 08/25/25
  • Expected Move (DTE 7) 0.80 (6.36%)
  • Put/Call Vol Ratio 0.03
  • Today's Volume 611
  • Volume Avg (30-Day) 869
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 28,171
  • Open Int (30-Day) 29,709
  • Expected Range 11.77 to 13.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.55
  • Number of Estimates 9
  • High Estimate 0.02
  • Low Estimate -0.84
  • Prior Year -0.63
  • Growth Rate Est. (year over year) +12.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.00 +25.70%
on 11/14/25
14.22 -11.60%
on 11/18/25
+1.36 (+12.13%)
since 11/11/25
3-Month
7.35 +71.02%
on 09/22/25
14.22 -11.60%
on 11/18/25
+4.76 (+60.95%)
since 09/11/25
52-Week
5.90 +113.05%
on 05/15/25
22.48 -44.08%
on 12/12/24
-9.97 (-44.23%)
since 12/11/24

Most Recent Stories

More News
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a chemotherapy-free combination approach in diffuse large B-cell lymphoma...

ARVN : 12.57 (-3.16%)
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

NEW HAVEN, Conn., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced...

ARVN : 12.57 (-3.16%)
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced...

ARVN : 12.57 (-3.16%)
PFE : 25.80 (+0.08%)
Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update

– Presented positive data from Phase 1 clinical trials with ARV-102 in healthy volunteers and patients with Parkinson’s disease – – Presented preclinical data from ARV-806 demonstrating robust...

ARVN : 12.57 (-3.16%)
Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc . (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced...

ARVN : 12.57 (-3.16%)
Arvinas to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced...

ARVN : 12.57 (-3.16%)
Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025

NEW HAVEN, Conn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced...

ARVN : 12.57 (-3.16%)
Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

– In vivo, ARV-806 demonstrated robust and durable KRAS G12D degradation, leading to significant tumor growth inhibition in models of pancreatic, colorectal, and lung cancer –  – Data underscore...

ARVN : 12.57 (-3.16%)
Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

NEW HAVEN, Conn., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced...

ARVN : 12.57 (-3.16%)
Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress

– Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN)...

ARVN : 12.57 (-3.16%)

Business Summary

Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States.

See More

Key Turning Points

3rd Resistance Point 13.68
2nd Resistance Point 13.41
1st Resistance Point 12.99
Last Price 12.57
1st Support Level 12.31
2nd Support Level 12.04
3rd Support Level 11.62

See More

52-Week High 22.48
Fibonacci 61.8% 16.15
Fibonacci 50% 14.19
Last Price 12.57
Fibonacci 38.2% 12.23
52-Week Low 5.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar